GW Pharmaceuticals PLC (NASDAQ:GWPH) had its price objective lowered by stock analysts at Bank of America Corporation from $160.00 to $158.00 in a research note issued on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America Corporation’s target price suggests a potential upside of 34.79% from the stock’s current price.

A number of other brokerages have also weighed in on GWPH. Maxim Group set a $135.00 price objective on GW Pharmaceuticals PLC and gave the company a “buy” rating in a report on Monday, August 7th. Zacks Investment Research lowered GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Monday, July 24th. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the company a “buy” rating in a report on Tuesday, August 8th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $124.00 price objective on shares of GW Pharmaceuticals PLC in a report on Friday, October 6th. Finally, ValuEngine raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. GW Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $144.55.

GW Pharmaceuticals PLC (NASDAQ GWPH) traded up $5.27 during trading on Tuesday, reaching $117.22. The company’s stock had a trading volume of 592,700 shares, compared to its average volume of 318,060. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.39 and a quick ratio of 10.26. GW Pharmaceuticals PLC has a 52 week low of $92.65 and a 52 week high of $136.95.

ILLEGAL ACTIVITY WARNING: “GW Pharmaceuticals PLC (GWPH) PT Lowered to $158.00” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/16/gw-pharmaceuticals-plc-gwph-pt-lowered-to-158-00.html.

Hedge funds have recently modified their holdings of the business. IHT Wealth Management LLC boosted its position in GW Pharmaceuticals PLC by 18.0% during the second quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 100 shares in the last quarter. Advisor Group Inc. boosted its position in GW Pharmaceuticals PLC by 10.7% during the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares in the last quarter. BNP Paribas Arbitrage SA purchased a new position in GW Pharmaceuticals PLC during the second quarter worth approximately $163,000. Woodmont Investment Counsel LLC purchased a new position in GW Pharmaceuticals PLC during the second quarter worth approximately $201,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in GW Pharmaceuticals PLC during the second quarter worth approximately $204,000. Institutional investors own 75.71% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.